CRISPR THERAPTC (NASDAQ:CRSP) Director Kurt Von Emster sold 34,141 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $19.06, for a total value of $650,727.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $19.59, for a total value of $1,088,596.71.
  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $18.63, for a total value of $660,861.99.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.81, for a total value of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.51, for a total value of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.63, for a total value of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $17.60, for a total value of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.84, for a total value of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.56, for a total value of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of CRISPR THERAPTC stock. The stock was sold at an average price of $16.26, for a total value of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of CRISPR THERAPTC stock. The shares were sold at an average price of $16.90, for a total value of $730,113.80.

Shares of CRISPR THERAPTC (NASDAQ:CRSP) traded down 0.43% on Friday, reaching $18.34. The company had a trading volume of 60,044 shares. CRISPR THERAPTC has a 52-week low of $11.63 and a 52-week high of $25.00. The firm’s market capitalization is $744.44 million. The company has a 50-day moving average price of $17.32 and a 200-day moving average price of $17.51.

CRISPR THERAPTC (NASDAQ:CRSP) last released its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. CRISPR THERAPTC had a negative return on equity of 47.46% and a negative net margin of 406.61%. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. CRISPR THERAPTC’s revenue for the quarter was up 350.0% on a year-over-year basis. Equities research analysts forecast that CRISPR THERAPTC will post ($2.43) EPS for the current fiscal year.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/18/crispr-theraptc-crsp-director-sells-650727-46-in-stock.html.

A number of large investors have recently added to or reduced their stakes in CRSP. Wellington Management Group LLP increased its stake in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock worth $16,272,000 after buying an additional 3,070 shares during the period. IHT Wealth Management LLC purchased a new stake in CRISPR THERAPTC during the first quarter worth $110,000. Wells Fargo & Company MN increased its stake in CRISPR THERAPTC by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares during the period. ARK Investment Management LLC purchased a new stake in CRISPR THERAPTC during the second quarter worth $206,000. Finally, Monashee Investment Management LLC increased its stake in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the period. 24.08% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently commented on CRSP shares. Chardan Capital reissued a “buy” rating on shares of CRISPR THERAPTC in a report on Monday. SunTrust Banks, Inc. started coverage on CRISPR THERAPTC in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price target for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a report on Tuesday, July 18th. Finally, Cann started coverage on CRISPR THERAPTC in a report on Monday, July 17th. They issued a “market perform” rating for the company. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $21.92.

CRISPR THERAPTC Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for CRISPR THERAPTC (NASDAQ:CRSP)

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.